Biotech Startups

DreamFold builds a protein therapeutics platform that uses AI-driven protein design, generative modelling, and high-throughput screening to develop new classes of protein drugs for diseases lacking effective treatments. It operates in the biotech and AI drug discovery space.

8 investors

KaloCyte develops ErythroMer, a dried, shelf-stable artificial red blood cell for use in emergency and trauma care when stored blood is unavailable or in short supply. The pre-clinical stage biotech company is supported by federal grants and investor funding.

8 investors

Level Zero Health develops electrochemical and microfluidic biosensor platforms for point-of-care and continuous diagnostic devices. The company serves healthcare providers and patients requiring faster, more accessible diagnostic solutions.

8 investors

Ligo develops computational tools for enzyme design by combining large language models with specialized neural networks to enable scientists and AI agents to discover new enzymes and biological functions.

8 investors

Lindus advances pharmaceutical asset portfolios through an integrated clinical trial platform, partnering with biotech and pharma companies to accelerate drug development. The company combines technology-enabled trial execution, direct patient recruitment, and real-time data access to run faster, higher-quality studies across all phases.

8 investors

March Bioscience is a cell therapy company assembling leading scientists and drug developers to advance cell therapy treatments. The company focuses on developing therapeutics in the cell and gene therapy space.

8 investors

Matterworks builds foundation models (its Large Spectral Model, delivered via the cloud-based Pyxis platform) that analyze biochemical omics and mass spectrometry data to make predictions for life science R&D. It serves discovery, toxicology, clinical development, and biomanufacturing teams with applications such as target discovery, toxicity prediction, and bioprocess optimization.

8 investors

Mercy BioAnalytics develops diagnostic tests for early cancer detection using advanced proteomics and genomics technologies. The company serves healthcare providers and patients seeking to improve cancer detection accuracy and timing.

8 investors

Metsera was a clinical-stage biotechnology company developing injectable and oral medicines for obesity and metabolic diseases, including next-generation GLP-1 and amylin-based therapies. Acquired by Pfizer in 2025.

8 investors

Michroma uses industrial biotechnology and fermentation to produce natural food colorants, offering an alternative to petrochemical-derived synthesis, plant extraction, and animal-based ingredients. It serves food and consumer product companies seeking healthier and more sustainable ingredients.

8 investors

Mission Bio develops single-cell biology tools and platforms for researchers and clinicians to enable precision medicine discovery and cancer treatment. The company serves the biomedical research and clinical diagnostics market.

8 investors

Monte Rosa develops molecular glue degrader (MGD) therapeutics using MGD chemistry, artificial intelligence, structural biology, and proteomics to target previously undruggable or inadequately drugged disease targets. The company operates in drug discovery and pharmaceutical development.

8 investors

Motif Neurotech develops a therapeutic brain-computer interface using minimally invasive neuromodulation to treat difficult-to-treat mental health conditions such as depression. The company builds implantable neurotechnology for patients with mental illness and is based in Houston, Texas.

8 investors

Multiply Labs develops cloud-controlled modular robotic systems that manufacture individualized drugs and deploys them in pharmaceutical customers' facilities, selling robotic production capacity as a service. It serves the pharma manufacturing industry producing individualized and next-generation therapies.

8 investors

Nabla is a drug development company that applies design discipline and scientific rigor to the development of new medicines. The company focuses on making drug development more systematic and iterative, serving the pharmaceutical and biotech industry.

8 investors

Nephrogen develops AI-powered AAV delivery vehicles for genetic medicines targeting kidney and pancreatic diseases. The company uses high-throughput in vivo screening to design tissue-specific viral vectors that are significantly more efficient and less immunogenic than existing alternatives.

8 investors

Nest Genomics develops genomics solutions to integrate genetic testing into routine patient care. The company is led by former Clear Genetics founders and employs genetic counselors and engineers.

8 investors

Neuros Medical develops the Altius Direct Electrical Nerve Stimulation System, an FDA-approved implantable device that delivers patient-controlled electrical stimulation to treat chronic post-amputation pain in adult lower limb amputees. The device targets phantom limb and residual limb pain, letting patients start therapy on demand.

8 investors

Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.

8 investors

Nimble Science develops SIMBA Capsule Kits that enable researchers and commercial partners to study the small intestinal microenvironment; the company offers discounted access to these kits in exchange for research data and provides regulatory and clinical support services.

8 investors

Nouscom is a biotech company whose investors page lists its venture capital backers. The page itself provides no description of the company's own products or operations.

8 investors

NVision develops quantum computing and quantum-enhanced sensing platforms based on quantum spin control in organic molecules, with focus on healthcare applications including drug development and disease treatment.

8 investors

Orca Bio develops allogeneic T-cell immunotherapies for high-risk blood cancers including acute myeloid leukemia, acute lymphocytic leukemia, and myelodysplastic syndrome. The company is advancing precision cell therapy treatments for patients with blood cancers and autoimmune diseases.

8 investors

Orum is a global biopharmaceutical company developing cancer therapies that combine protein degraders with antibodies. It focuses on Degrader Antibody Conjugate (DAC) technology to research and develop new therapeutics.

8 investors